Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.

International journal of cancer - 1 Sept 2012

Andersen Niels F, Vogel Ulla, Klausen Tobias W, Gimsing Peter, Gregersen Henrik, Abildgaard Niels, Vangsted Annette J

Abstract excerpt

Vascular endothelial growth factor (VEGF) is a potent proangiogenic factor. Several single nucleotide polymorphisms (SNPs) in the VEGF gene with influence on VEGF expression have been described. In multiple myeloma, VEGF stimulates angiogenesis which is correlated with disease progression and prognosis. In this study, we evaluated the association between genetic variations in the VEGF gene in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haplotypes

Share to Multiple Myeloma

Share to Prognosis

Share to Survival Rate

Share to Thalidomide

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 22139971
DOI: 10.1002/ijc.27387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.PMID 22139971Read ↗

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.Semantic proximity Read ↗

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.Semantic proximity Read ↗

Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients.Semantic proximity Read ↗

bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients.Semantic proximity Read ↗

Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.Semantic proximity Read ↗

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.Semantic proximity Read ↗

Genetic variations in multiple myeloma II: association with effect of treatment.Semantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

Effects of TNFα, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases.Semantic proximity Read ↗

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.Semantic proximity Read ↗

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.